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Abstract 
 
 
Aim: To evaluate the response to recombinant GH treatment in short chil-
dren with CHARGE syndrome. 
Patients: We identified 51 children (28 boys, 23 girls) in KIGS (Pfizer Inter-
national Growth Database). Median chronological ages (CA) at GH start was 
7.6 yr and at the latest visit 13.2 yr. Evaluation for GHD (n= 33): GH peak 7.3 
μg/L and IGF-I -2.01 SDS. Sixteen subjects (9 boys) were followed longitudi-
nally for 2 yrs.  
Results (median SDS): Birth length (-0.47) and weight (-0.97) were slightly 
reduced. At GH start, Height (Ht) was -3.6, BMI - 0.7 and GH dose 0.26 
mg/kg/wk.  At latest visit after 2.7 yrs of GH, Ht had increased to -2.2 and 
BMI to -0.5.  
Longitudinal group (start, 1 yr, and 2 yr): Ht increased from -3.72 to -2.92 to  
-2.37 (start - 2 yr: p<0.05), Ht velocity increased from -1.69 to 2.98 to 0.95, 
BMI and GH dose (mg/kg/wk) remained almost unchanged.   
Conclusions: Our data show a positive effect of conventional doses of GH 
on short-term growth velocity for the longitudinal as well as for the total 
group, without any safety issues.    
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Introduction 
 
CHARGE is an acronym proposed by Pagon et al [1] to describe a syndrome 
(OMIM 214800) with multiple congenital anomalies such as coloboma of the 
eye, heart malformations, choanal atresia, retardation of growth and mental 
development, genitourinary anomalies, and ear malformations [2-6]. 
CHARGE syndrome is a clinical diagnosis based on major and minor criteria 
as outlined by Blake et al. and Verloes [4, 7]. Mutations of the chromodomain 
helicase DNA-binding protein gene, CHD7, were reported to be a major 
cause of CHARGE syndrome [2, 8, 9].  
 
Children with CHARGE syndrome have also endocrine disturbances which 
affect genital development, puberty and growth. Puberty is often delayed or 
absent due to hypogonadotropic hypogonadism in combination with anosmia 
[10-12]. Studies show that postnatal growth is disturbed in 37-72% of affect-
ed children [13-15]. It has generally been assumed that short stature is 
caused by recurrent infections, feeding problems, and/or hospitalizations, 
and not due to a hormonal insufficiency. However, growth hormone (GH) de-
ficiency has been reported in children with CHARGE syndrome [12, 13, 16, 
17].  
 
To the best of our knowledge, there are no published data in the literature on 
the effects of GH treatment in short children with CHARGE syndrome. The 
aim of the present study was to evaluate the effects of GH treatment on 
growth and BMI in children with CHARGE syndrome.   
Patients and Methods  
 
The data of 51 children (28 boys, 23 girls) with the diagnosis CHARGE syn-
drome were retrieved from the pharmaco-epidemiological survey, KIGS 
(Pfizer International Growth data base), in 2012 [18]. We assume that the 
diagnosis was made by clinical geneticists according to the criteria defined by 
Blake et al. and Verloes [4, 7]. Data on molecular confirmation of the  
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diagnosis were not recorded in the database. The children were treated with 
GH (Genotropin®) by s.c.-injections 6 or 7 days per week. The results of a 
pharmacological GH stimulation test were documented in 33 patients. Medi-
an (10 – 90 percentiles) peak GH (µg/L) was 7.3 (2.7 - 15.5). Fifteen children 
had a GH peak < 10 µg/L and were considered GH- deficient. The median 
serum IGF-I level was – 2.0 SDS (-3.2 - 0.7). The median chronological age 
(CA) at the start of GH therapy was 7.6 yr (2.2 –14.7 yr), with 3 subjects in 
puberty. At the latest available visit, the median age was 13.2 yr (4.6 - 18.5) 
and 19 subjects were in puberty. The median starting dose of GH was 0.26 
mg/kg/week. The median duration of GH treatment was 2.7 yr (0.35 – 8.8 yr). 
Bone age results were not documented.   
 
Of the total group, the longitudinal auxological data of 16 prepubertal children 
(9 boys, 7 girls) who remained prepubertal for at least 2 yrs during GH treat-
ment were analyzed.  The median CA at start of GH for those was 6.9 yr (2.2 
- 12.5 yr).  
SDS values for birth data, height (H), height velocity (HV), and BMI were cal-
culated based on Swedish, Swiss, and Great Britain references [19-21]. The 
results, where appropriate, are shown as median (10th - 90th percentile) or 
mean (SD). Student’s T-test  was used for comparisons of outcome 
measures when applicable otherwise Wilcoxon rang sum test was used, con-
sidering difference at less than 5% level as significant (p<0.05). Statistical 
analysis was made by SAS (SAS Institute, Cary, NC 27513-2414, USA). 
Results 
 
Cross-sectional data of the total group  
 
In the total group, median (P10 to 90) birth length was -0.47 SDS (-2.3 - 1.4), 
and birth weight SDS was -0.97 (-2.8 - 1.2). Table 1 shows the auxological 
data of the children at start of GH and at the latest documented visit in KIGS. 
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At the start of GH therapy, data on Ht velocity (HtV) were only available for 
10 patients. Median HtV was 4.4 cm/yr (2.3 - 10.3 cm/yr).  
As shown in Table 1, the children were very short at the start of GH treatment 
(Ht SDS P90 -2.4). On GH, median height SDS increased from -3.6 to -2.2 
SDS at the last documented visit, whereas median BMI SDS remained un-
changed. The median duration of GH therapy was 2.7 yr. The first-year HtV 
during GH treatment was not different between children with and without GH 
deficiency.  
 
Two-year longitudinal data 
 
The longitudinal data of 16 children from start of GH therapy, at 1 yr, and at 2 
yr on GH treatment are shown in Table 2. All children remained prepubertal 
during the observation period. Peak GH levels were reported for 11 patients 
(9 with GHD and 2 with non-GHD); no information was available for 5 pa-
tients. Plotting the peak GH levels versus delta height SDS for one-year pre-
pubertal growth, a weak and not significant correlation (r = -0.19) was found. 
The median (P10-90) starting dose of GH was 0.23 mg/kg/wk (0.17 - 0.34). 
Median Ht-SDS increased significantly from -3.7 at the start to -2.4 at 2 yr 
(p<0.05) (Fig. 1). Ht-SDS minus mid-parental Ht-SDS also increased signifi-
cantly from -3.4 at the start to -2.1 at 2 yr of GH treatment (p<0.05).  
During the 2 years of GH treatment, median HV-SDS increased from -1.7 to 
0.95, and median BMI-SDS remained almost unchanged (-1.3 to -1.4). The 
median change in Ht-SDS in the first year of GH treatment was +0.79 and, in 
the second year, +0.46. The dose of GH remained unchanged during the first 
2 yrs of treatment.  
 
Adverse events 
 
Adverse events (AEs) were reported in seven children: upper respiratory tract 
infection (n = 3) and one each with viral gastroenteritis, chickenpox, head-
ache, and kyphoscoliosis.    
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Discussion 
 
This is the first report showing efficacy and safety data on the growth out-
comes and adverse events in GH-treated short children with CHARGE syn-
drome. All children were found to have a substantial improvement in height 
SDS and height velocity SDS after 1 and 2 years of GH treatment, while BMI 
SDS remained unchanged. The gain in height SDS (start vs latest visit) of the 
total group was +1.3 SDS. Starting age was however relative high and many 
children entered puberty only after some months on treatment, which could 
contribute to overestimation of efficacy. However, the same results were 
found when only a prepubertal subgroup was analyzed.  
 
It has been shown that children with CHARGE syndrome usually have a 
normal birth weight and birth length [13, 22]. The birth data of our group con-
firm these results. The majority of children with CHARGE syndrome experi-
ence decelerated growth pattern during late infancy [10, 13-15, 23]. It has 
been speculated that the etiology of short stature is multifactorial due to car-
diac malformations, infections, feeding problems, gastro-esophageal reflux, 
choanal atresia, and/or recurrent hospitalizations [3, 13] and not due to en-
docrine disorders such as growth hormone deficiency. The low BMI values, 
both at start and during GH therapy, confirm that nutrition is a major problem 
in children with Charge syndrome.  
 
Growth hormone deficiency has been documented in some children with 
CHARGE syndrome [12, 13, 16, 17]. Pinto et al. assessed GH secretion in 25 
short children with CHARGE syndrome [12] and three had low peak GH val-
ues consistent with GHD. Asakura et al. found GHD in one of seven patients 
with CHARGE syndrome [16], and Husu et al. reported GHD in three of nine 
short children with CHARGE syndrome  [14]. In the KIGS cohort, a pharma-
cological GH stimulation test was documented in only 33 patients with a low 
GH result (<10 µg/L) in 15. The high incidence of GHD in our population can 
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be explained by a recruitment bias, since the data were extracted from a GH 
database.  
The weak correlation between peak GH levels versus delta height SDS for 
one-year prepubertal growth may indicate that endogenous GH status does 
not appear to play a role in the first-year height response to GH therapy, but 
the cohort may be too small to be certain. The reported adverse events are 
harmless and in parallel to previous reports in other GH indications [24]. In 
order to recommend treatment with GH in these patients, it is necessary to 
have long-term data on GH and particularly final height data. However, it is 
important to carry out a careful evaluation of the hypothalamic-pituitary axis 
in children with CHARGE syndrome.  
Our study has several limitations. There might be a selection bias since only 
very short-statured patients with CHARGE syndrome were selected for GH 
therapy. Additionally, there were children who were treated with GH without 
proven GH deficiency. Moreover, we have no genetic confirmation of the di-
agnosis in our subjects.   
 
In summary, here we present short-term longitudinal outcome to treatment 
with GH in children with CHARGE syndrome. GH was effective in improving 
linear growth over the first years on treatment, also when a prepubertal sub-
set was studied. However, long-term data on GH and final height data are 
unfortunately lacking.  
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Table 1  
Auxological data (Median; 10th – 90th percentile) of the whole group of         
51 children with CHARGE at the start of GH and at the latest documented 
visit in KIGS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CA = chronological age; H = height; SDS = standard deviation score;               
MPH = midparental height; BMI = body mass index; GH = growth hormone
 Background 
Birth weight SDS 
(n = 47) 
-0.97 (2.77 - 1.16) 
Birth length SDS 
(n = 36) 
-0.47 (2.30 - 1.40) 
Max GH peak µg/L 
(n = 33) 
7.30 (2.70 - 15.5) 
IGF-I SDS 
(n = 23) 
-2.01 (-3.24 - 0.66) 
 At GH start At last visit 
CA (yr) 
(n = 51) 
7.6 
(2.2 - 14.7) 
13.2 
(4.6 - 18.5) 
In puberty N = 3 N =19 
H-SDS 
(n = 51) 
-3.6 
(-5.5  -  -2.4) 
-2.2 
(-5.2  -  -0.6) 
H-SDS corrected 
with MPH-SDS 
(n = 44) 
-3.3 
(-4.6  -  -1.6) 
-1.7 
(-3.5  -  -0.3) 
BMI SDS 
(n = 51) 
-0.7 
(-2.6  - 1.3) 
-0.5 
(-2.6  - 1.7) 
GH dose 
(mg/kg/wk) 
(n = 51) 
0.26 
(0.18  -  0.37) 
0.28 
(0.18  - 0.36) 
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Table 2 Longitudinal data of 16 children with CHARGE syndrome in  
  KIGS who remained prepubertal during 2 yr of GH therapy  
   
  N Median 
   
    10th         90th     Mean SD 
At GH start  
      CA (yr) 16 6.86 2.17 12.5 7.52 4.43 
Height (H; cm) 16 99.2 75.5 127.7 102.6 22.4 
H-SDS 16 -3.72 -5.63 -2.80 -4.03 1.29 
H – MPH (SDS) 16 -3.44 -5.79 -1.95 -3.54 1.26 
Height velocity (HV; cm/yr) 4 3.98 2.72 4.82 3.88 0.91 
HV-SDS 4 -1.69 -3.36 0.35 -1.60 1.95 
BMI-SDS 16 -1.32 -3.58 0.60 -1.28 1.41 
hGH (mg/kg/wk) 16 0.23 0.17 0.34 0.25 0.08 
1st year on GH  N Median 10th 90th Mean SD 
CA (yr) 16 7.91 3.03 13.6 8.53 4.48 
Height (cm) 16 106.9 83.2 135.6 111.6 21.6 
H-SDS 16 - 2.92 - 5.17 - 1.91 - 3.29 1.61 
H – MPH (SDS) 16 - 2.50 - 5.35 - 1.18 - 2.81 1.43 
Height velocity (cm/yr) 16 8.82 6.29 10.5 8.92 2.80 
HV-SDS 16 2.98 - 0.31 6.38 2.93 2.69 
Delta H-SDS (1st yr vs start) 16 0.79 0.45 1.14 0.73 0.43 
BMI-SDS 16 - 1.19 - 3.58 0.19 - 1.42 1.45 
hGH (mg/kg/wk) 16 0.24 0.18 0.35 0.26 0.07 
2nd year on GH  N Median 10th 90th Mean SD 
CA (yr) 16 8.87 4.17 14.5 9.52 4.42 
Height (cm) 16 112.1 93.8 141.9 118.8 20.4 
H-SDS 16 -2.37 -4.74 -1.63 -2.89 1.83 
H – MPH (SDS)  16 -2.11 -4.20 -0.72 -2.40 1.54 
Height velocity (cm/yr) 16 7.19 4.82 9.31 7.28 2.10 
HV-SDS 16 0.95 -0.88 4.74 1.53 3.19 
Delta H-SDS (2nd yr vs 1st yr) 16 0.46 -0.28 1.04 0.41 0.49 
BMI SDS 15 -1.44 -2.73 0.15 -1.26 1.30 
hGH (mg/kg/wk) 16 0.24 0.18 0.36 0.26 0.08 
CA = chronological age; H = height; SDS = standard deviation score;    
MPH = midparental height; BMI = body mass index; hGH = growth hormone 
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Fig. 1   
Longitudinal height data (SDS) of 16 prepubertal children with CHARGE syndrome on GH 
therapy at start, at 1. and 2. yr.  
(Box plot with individual height during GH treatment; median value, box 25th and 75th  
percentile; whiskers 10th and 90th percentile). 
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